Published in Neoplasia on July 01, 2008
Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene (2009) 1.85
MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia (2010) 1.37
Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia (2010) 1.36
Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. PLoS One (2012) 1.25
Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha. Neoplasia (2010) 1.07
Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia (2009) 1.05
Targeting cancer cell metabolism in pancreatic adenocarcinoma. Oncotarget (2015) 1.05
Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer (2009) 1.03
Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation. Int J Cancer (2014) 1.01
Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Front Physiol (2014) 1.00
Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer (2011) 0.98
Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget (2015) 0.96
MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene (2012) 0.95
Differential roles of cyclin D1 and D3 in pancreatic ductal adenocarcinoma. Mol Cancer (2010) 0.94
MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol (2011) 0.93
Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J Gastroenterol (2014) 0.92
Prospectively isolated cancer-associated CD10(+) fibroblasts have stronger interactions with CD133(+) colon cancer cells than with CD133(-) cancer cells. PLoS One (2010) 0.92
Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma. Transl Oncol (2013) 0.89
Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole. Br J Cancer (2015) 0.88
Hypoxia-inducible factors: mediators of cancer progression; prognostic and therapeutic targets in soft tissue sarcomas. Cancers (Basel) (2013) 0.87
BMP-specific SMADs function as novel repressors of PDGFA and modulate its expression in ovarian granulosa cells and tumors. Oncogene (2012) 0.86
Mapping the epistatic network underlying murine reproductive fatpad variation. Genetics (2010) 0.85
EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma. PLoS One (2013) 0.84
Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment. Br J Cancer (2013) 0.84
Extracellular superoxide dismutase suppresses hypoxia-inducible factor-1α in pancreatic cancer. Free Radic Biol Med (2014) 0.84
The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. Stem Cell Rev (2015) 0.84
Hypoxia-induced endoplasmic reticulum stress characterizes a necrotic phenotype of pancreatic cancer. Oncotarget (2015) 0.83
A cell-penetrating peptide suppresses the hypoxia inducible factor-1 function by binding to the helix-loop-helix domain of the aryl hydrocarbon receptor nuclear translocator. Chem Biol Interact (2013) 0.82
Hypoxia Inducible Factor 1 (HIF-1) Recruits Macrophage to Activate Pancreatic Stellate Cells in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci (2016) 0.82
Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma. HPB (Oxford) (2016) 0.82
Anti-pancreatic cancer deliverables from sea: first-hand evidence on the efficacy, molecular targets and mode of action for multifarious polyphenols from five different brown-algae. PLoS One (2013) 0.80
Emerging therapies in pancreas cancer. J Gastrointest Oncol (2011) 0.80
Mucins in neoplasms of pancreas, ampulla of Vater and biliary system. World J Gastrointest Oncol (2016) 0.79
Pancreatic head carcinoma and vascular endothelial growth factor (VEGF-A) concentration in portal blood: its association with cancer grade, tumor size and probably poor prognosis. Arch Med Sci (2014) 0.79
FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. BMC Cancer (2016) 0.79
Circulating Tumor Cell Composition in Renal Cell Carcinoma. PLoS One (2016) 0.78
Nonantibiotic Effects of Fluoroquinolones in Mammalian Cells. J Biol Chem (2015) 0.78
The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines. J Exp Clin Cancer Res (2015) 0.78
SCF, regulated by HIF-1α, promotes pancreatic ductal adenocarcinoma cell progression. PLoS One (2015) 0.77
Hypoxia inducible factor-1 alpha and multiple myeloma. Int J Adv Res (Indore) (2016) 0.76
HIF-1α -1790G>A polymorphism significantly increases the risk of digestive tract cancer: a meta-analysis. World J Gastroenterol (2015) 0.76
β2-adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1α. Oncotarget (2016) 0.75
Dinosaurs and ancient civilizations: reflections on the treatment of cancer. Neoplasia (2010) 0.75
Molecular Pathways Controlling Autophagy in Pancreatic Cancer. Front Oncol (2017) 0.75
Neoplasia: the second decade. Neoplasia (2008) 0.75
The War on Cancer rages on. Neoplasia (2009) 0.75
Autocrine DUSP28 signaling mediates pancreatic cancer malignancy via regulation of PDGF-A. Sci Rep (2017) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A (1995) 24.77
TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer (1997) 5.80
Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem (1996) 5.15
Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer (2001) 3.10
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res (1995) 3.04
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem (2000) 2.53
HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene (2005) 2.53
Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene (2000) 2.47
Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg (2000) 1.59
Molecular determinants of cetuximab efficacy. J Clin Oncol (2005) 1.56
Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol (2007) 1.55
Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology (2005) 1.47
Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res (2006) 1.39
Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg (2002) 1.35
Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol (2007) 1.35
Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer (2005) 1.24
Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res (2005) 1.23
Pancreatic cancer mortality in Europe: the leveling of an epidemic. Pancreas (2003) 1.06
Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg (2005) 1.00
Hypoxia inducible factor-1 mediates effects of insulin on pancreatic cancer cells and disturbs host energy homeostasis. Am J Pathol (2007) 0.91
Effect of HIF-1alpha on VEGF-C induced lymphangiogenesis and lymph nodes metastases of pancreatic cancer. J Huazhong Univ Sci Technolog Med Sci (2006) 0.84
Targeting of the VHL-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapy. J Am Soc Nephrol (2003) 0.84
Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater. World J Gastroenterol (2006) 0.80
MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene (2003) 7.90
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology (2008) 3.00
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res (2002) 2.96
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol (2007) 2.83
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res (2004) 2.54
Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol (2011) 2.51
Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med (2008) 2.29
Early gastric cancer: lymph node metastasis starts with deep mucosal infiltration. Ann Surg (2009) 2.07
Preoperative vs. postoperative radiochemotherapy in patients with N2 squamous cell carcinoma of the oral cavity. Oral Oncol (2012) 2.00
Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res (2002) 1.88
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene (2003) 1.88
Improving informed consent of surgical patients using a multimedia-based program? Results of a prospective randomized multicenter study of patients before cholecystectomy. Ann Surg (2008) 1.74
Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res (2004) 1.70
Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol (2006) 1.70
Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg (2005) 1.60
Prognostic relevance of skip metastases in esophageal cancer. Ann Thorac Surg (2010) 1.59
Molecular determinants of cetuximab efficacy. J Clin Oncol (2005) 1.56
Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg (2008) 1.55
Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test. Arch Pathol Lab Med (2012) 1.53
Prognostic significance of a new grading system of lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer. Ann Thorac Surg (2011) 1.50
High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res (2004) 1.50
Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther (2006) 1.49
Endoscopic therapy for esophageal perforation or anastomotic leak with a self-expandable metallic stent. Surg Endosc (2009) 1.47
High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res (2005) 1.46
Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. World J Surg (2010) 1.45
Podoplanin expression in cutaneous head and neck squamous cell carcinoma--prognostic value and clinicopathologic implications. J Surg Oncol (2012) 1.44
S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res (2004) 1.41
Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res (2006) 1.39
Dendritic cells are significantly reduced in non-Hodgkin's lymphoma and express less CCR7 and CD62L. Leuk Lymphoma (2006) 1.39
XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer. J Surg Res (2010) 1.39
MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia (2010) 1.37
The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep (2008) 1.34
Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol (2012) 1.34
Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology (2005) 1.32
Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res (2009) 1.30
Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. PLoS One (2013) 1.27
Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res (2004) 1.24
Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics (2007) 1.23
A three-gene signature for outcome in soft tissue sarcoma. Clin Cancer Res (2009) 1.23
Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res (2005) 1.22
Submandibular gland excision: 15 years of experience. J Oral Maxillofac Surg (2007) 1.22
Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res (2006) 1.18
HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer (2004) 1.16
Depletion of neutrophil extracellular traps in vivo results in hypersusceptibility to polymicrobial sepsis in mice. Crit Care (2012) 1.16
Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a retrospective comparison with conventional endoscopic resection in a single center. Gastric Cancer (2013) 1.16
Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int J Oncol (2011) 1.15
Quantitative promoter methylation analysis of hepatocellular carcinoma, cirrhotic and normal liver. Int J Cancer (2008) 1.15
High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res (2004) 1.14
Artificial neural network for prediction of lymph node metastases in gastric cancer: a phase II diagnostic study. Ann Surg Oncol (2004) 1.13
Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surgery (2005) 1.11
Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol (2014) 1.11
Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res (2003) 1.10
A concerted action of HNF4alpha and HNF1alpha links hepatitis B virus replication to hepatocyte differentiation. Cell Microbiol (2008) 1.10
A phase II study of endoscopic submucosal dissection for superficial esophageal neoplasms (KDOG 0901). Gastrointest Endosc (2013) 1.10
The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer. Clin Cancer Res (2010) 1.09
Mutations in the mitochondrial DNA D-Loop region occur frequently in adenocarcinoma in Barrett's esophagus. Oncogene (2002) 1.09
Primary intraosseous carcinoma of the jaws arising from an odontogenic cyst--a case report. J Craniomaxillofac Surg (2004) 1.09
ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J Gastrointest Surg (2009) 1.07
Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep (2007) 1.05
Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer. Anticancer Res (2009) 1.04